Evaluation of long-term results of the use of entomological drug in the combination therapy of patients with benign prostatic hyperplasia and chronic prostatitis

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access


Introduction. Benign prostatic hyperplasia (BPH) and chronic prostatitis (CP) are among the most important urological diseases. The right choice of treatment for patients with BPH and CP continues to be contradictory. Recently, a new group of entomological drugs has been increasingly used, one of which is Adenoprosin®. Aim. To study the efficiency of Adenoprosin® as part of combination therapy, as well as to evaluate the long-term outcomes in patients with BPH and CP. Materials and methods. A total of 60 patients with BPH and CP were included in the study. They were randomized into two groups of 30 each. In the comparison group, traditional therapy with a1-blockers and fluoroquinolones was administered. In the main group, similar therapy was prescribed in combination with Adenoprosin for 6 months. The follow-up period was 12 months. Results. At baseline, the groups were homogeneous. After three and six months, the results in the control group did not significantly improve, but negative dynamics was revealed at visit 4. The results obtained in the main group at visits 3 and 4 were also significantly better (p<0.05) compared to the control group. During 12 months of follow-up, 7 (23.3%) cases of recurrent CP in the comparison group and 1 (3.3%) case in the main group were seen. Conclusion. According to our results, the use of Adenoprosin® for 6 months allowed more effectively to reduce the lower urinary tract symptoms. The obtained effect persisted for the next 6 months, as evidenced by the dynamics of the studied indicators and the relapse rate of CP.

Full Text

Restricted Access

About the authors

A. V Kuzmenko

FGBOU VO «Voronezh State Medical University named after N.N. Burdenko

Email: kuzmenkoav09@yandex.ru
MD, associate professor, Head of Department of Urology Voronezh, Russia

V. V Kuzmenko

FGBOU VO «Voronezh State Medical University named after N.N. Burdenko

Email: kuzmenkovv2003@mail.ru
MD, professor, professor at the Department of Specialized Surgical disciplines Voronezh, Russia

T. A Gyaurgiev

FGBOU VO «Voronezh State Medical University named after N.N. Burdenko

Email: gta001100@yandex.ru
Ph.D., associate professor at the Department of Specialized Surgical disciplines Voronezh, Russia

G. A Kuzmenko

FGBOU VO «Voronezh State Medical University named after N.N. Burdenko

Email: KGA00110009@yandex.ru
second-year student of the Pediatric faculty Voronezh, Russia


  1. Урология. Российские клинические рекомендации. Под ред. Ю.Г. Аляева, П.В. Глыбочко, Д.Ю. Пушкаря. М.: ГЭОТАР-Медиа; 2018. 480 с.
  2. Gravas S., Cornu J.N., Drake M.J. et al. EAU guidelines on the management of non-neurogenic male lower urinary tract symptoms (LUTS), incl. benign prostatic obstruction (BPO). 2018. Available at: http://uroweb.org/guideline/treatment-of-non-neurogenic-male-luts/ Accessed 5 May 2019
  3. Schaeffer A.J. Classification (Traditional and National Institutes of Health) and Demographics of Prostatitis/ Urology. 2002 Dec;60(6 Suppl):5-6; discussion 6-7. doi: 10.1016/s0090-4295(02)02292-6.
  4. Nickel J. Prostatitis. CUA Guidelines. Canadian Urol. Assoc. J.,2011;5(5):306-315. https://www.ncbi.nlm.nih.gov/pubmed/22031609
  5. Rees J., Abrahams M., Doble A., Cooper A. and the Prostatitis Expert Reference Group (PERG). Diagnosis and treatment of chronic bacterial prostatitis and chronic prostatitis/chronic pelvic pain syndrome: a consensus guideline. BJU Int., 2015;116:509-525. 10.1111/bju.13101' target='_blank'>https://doi: 10.1111/bju.13101
  6. Gupta N., Rogers T., Holland B, Helo S., Dynda D., McVary K. T.Three-Year Treatment Outcomes of Water Vapor Thermal Therapy Compared to Doxazosin, Finasteride and Combination Drug Therapy in Men with Benign Prostatic Hyperplasia: Cohort Data from the MTOPS Trial. J Urol. 2018 Aug;200(2):405-413. doi: 10.1016/j.juro.2018.02.3088.
  7. Roehrborn C.G., Barkin J., Tubaro A., Emberton M., Wilson T.H. Brotherton B.J., Castro R.P. Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study. BJU Int. 2014 Apr;113(4):623-635. doi: 10.1111/bju.12500.
  8. Roehrborn C.G., Barkin J., Siami P., Tubaro A., Wilson T.H., Morrill B.B., Gagnier R.P. Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-year results from the randomized, double-blind Combination of Avodart and Tamsulosin (CombAT) trial. BJU Int. 2011 Mar;107(6):946-954. doi: 10.1111/j.1464-410X.2011.10124.x.
  9. Roehrborn, C.G., Oyarzabal Perez I., Roos E.P., Calomfirescu N., Brotherton B., Wang F., Palacios J.M., Vasylyev A., Manyak M.J. Efficacy and safety of a fixed-dose combination of dutasteride and tamsulosin treatment (Duodart) compared with watchful waiting with nitiation of tamsulosin therapy if symptoms do not improve, both provided with lifestyle advice, in the management of treatment-naive men with moderately symptomatic benign prostatic hyperplasia: 2-year CONDUCT study results. BJU Int. 2015;7. doi: 10.1111/bju.13033.
  10. Kudryavtsev Yu.V., Sivkov A.V. Morphological changes in prostate tissue in benign hyperplasia. Experimental and clinical urology. 2010;1:18-22.
  11. Aboyan I.A., Tolmachev A.N., Lemeshko S.I. Morphological characteristics of hyperplastic prostate tissue in chronic prostatitis. Experimental and clinical urology. 2020;13(4):82- 88.
  12. Krsmanovic A., Tripp D., Nickel J. et al. Psychosocial mechanisms of the pain and quality of life relationship for chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). Canadian Urological Association Journal, 2014;8 (11-12):403-408. 10.5489/cuaj.2179' target='_blank'>https://doi: 10.5489/cuaj.2179
  13. Kuzmenko A.V., Kuzmenko V.V., Gyaurgiev T.A.Combined drug therapy of patients with BPH. Urologiia. 2018;1:101-105.
  14. Kuzmenko A.V., Gyaurgiev T.A., Kuzmenko G.A. Our experience of using hexane extract of Serenoa Repens fruit (Permixone) in the treatment of LUTS in clinical practice Urologiia. 2022;2:84-89.
  15. Kuzmenko A.V., Kuzmenko V.V., Gyaurgiev T.A., Barannikov I.I. Chronobiological status of patients with chronic prostatitis on the background of prostate adenoma. System analysis and management in biomedical systems. 2017;16(3):513-316.
  16. Gandaglia G., Briganti A., Gontero P., et al. The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (BPH). BJU. 2013;112(4):432-441.doi: 10.1111/bju.12118.
  17. Alyaev Yu. G., Gadzhieva Z.K., Rapoport L.M., Kazilov Yu.B. Medical treatment of lower urinary tract symptoms in men. The role of uroselectivity in drug selection. Andrology and genital surgery. 2014;1:6-14.
  18. Gadzhieva Z.K., Kazilov Yu.B. New possibilities of treatment of combined symptoms of the lower urinary tract in patients with benign prostatic hyperplasia - prerequisites and advantages. Urologiia. 2017;1:95-102.
  19. Neymark A.I., Neymark B.A., Torbik D.V. Tactics of managing a patient with benign prostatic hyperplasia with a large volume of it. Bulletin of medical science. 2017;1 (5):44-53.
  20. Olariu L. et al. Entomological complex with pro-apoptotic and antiproliferative effect on prostatic dysplasia cells, EUROINVENT Cat., Timisoara, 2017.
  21. Dumbraveanu I., Banov P., Arian I., Tanase A. Use of entomological drugs in the complex treatment of patients with chronic prostatitis and erectile dysfunction. Moldovan Journal of Health Sciences. 2017;14(4).
  22. https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=9f4b8b0c-d1fd-495e-9cf6-1e837e8870e2
  23. Ghicavii V., Tanase A., Ceban E., Dumbraveanu I., Ciuhrii V. New Direction in the Treatment of Benign Prostate Hyperplasia Using Adenoprosin: Biologically’ Active Entomological Medicine. Urology.2011;78.
  24. Al-ShukriA.S., Kostyukov S.V., MaksimovaA.V. Evaluation ofthe effectiveness of the use of the entomological drug Adenoprosin® in combination therapy of patients with lower urinary tract symptoms caused by benign enlargement of the prostate gland. Urological reports. 2021;11(4):337-344. Doi: 10.17816/ uroved89410.
  25. Medvedev V.L., Efremov M.E. Efficacy of the drug Adenoprosin® in the complex treatment of patients with chronic bacterial prostatitis. Innovative medicine of Kuban. 2020;(3):45-51. https://doi.org/10.35401/2500-0268-2020-19-3-45-51
  26. Ibishev H.S., Kogan M.I., Naboka Y.L., Ismailov R.S. Efficacy and safety of Adenoprosin in chronic recurrent bacterial prostatitis with multiple resistance of uropathogens isolated from prostate secretions to antibacterial drugs. Questions of urology and andrology. 2021; 9(4): 5-13. doi: 10.20953/23076631-2021-3-5-13.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies